Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 11Completed 6Active not recruiting 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Follicular 8Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Mantle-Cell 4Lymphoma, B-Cell, Marginal Zone 3Leukemia, B-Cell 3Neoplasms 2Leukemia 2Burkitt Lymphoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Neoplasm, Residual 1Mesothelioma 1Melanoma 1Mature B-Cell Malignancies 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Hairy Cell 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Rituximab 13Cyclophosphamide 10Lenalidomide 8venetoclax 5ibrutinib 5fludarabine 4CT-P10 4orelabrutinib 3obinutuzumab 3fludarabine phosphate 3Vincristine 3tafasitamab 2pirtobrutinib 2copanlisib 2acalabrutinib 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Prednisone 2Nivolumab 2Mycophenolic Acid 2Melphalan 2Magnetic Resonance Spectroscopy 2Hyaluronoglucosaminidase 2Etoposide 2Doxorubicin 2Busulfan 2Bendamustine Hydrochloride 2selinexor 1prednylidene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, B-Cell, Marginal Zone × obinutuzumab × Clear all
NCT03322865 2026-05-06

Obinutuzumab in Marginal Zone Lymphoma

University of Ulm

Phase 2 Active not recruiting
56 enrolled
Lymphoid

Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT05783596 2026-03-16

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT02992522 2025-09-09

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Active not recruiting
22 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡